🇺🇸 FDA
Patent

US 11034660

Hydrazide containing nuclear transport modulators and uses thereof

granted A61KA61K31/4196A61K31/4439

Quick answer

US patent 11034660 (Hydrazide containing nuclear transport modulators and uses thereof) held by Karyopharm Therapeutics Inc. expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Karyopharm Therapeutics Inc.
Grant date
Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/4196, A61K31/4439, A61K31/454, A61K31/496